Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
Go back to Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 4c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 17.78 +0.51 (2.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.27 | 52 Week High | $0.19 | |||
| Open | $17.07 | 52 Week Low | $0.07 | |||
| Day High | $17.80 | P/E | N/A | |||
| Day Low | $16.87 | EPS | $-0.01 | |||
| Volume | 1,003,154 | |||||
